Stabilization of cyclic peptide structures
OwnerRonald C. Geyerinventor
Life of this patent
Estimating the term…
Abstract
In various aspects, the invention provides methods for cyclizing proteins, including methods for enhancing the stability of cyclized proteins under cytosolic conditions. The invention also provides various methods for using the cyclized proteins. For example, cyclized proteins of the invention may be used in screening assays analogous to the yeast two hybrid assay. Selected embodiments of the invention provide cyclized single chain variable fragment (ScFv) molecules, including molecules in the form of an immunoglobulin fold.
Claims18
A recombinant nucleic acid sequence encoding a split intein polypeptide, wherein the split intein polypeptide comprises, in amino to carboxy order:
- an ICdomain comprising an F block and a G block, the F block being at least 80% identical to the sequence rVYDLpV**a--HNFh, designated respectively as positions F1 to F16, and the G block being at least 80% identical to the sequence NGhhhHNp, designated respectively as positions G1 to G8;
- an extein domain attached to the C terminal portion of the G block;
- and,
- an IN domain attached to the C terminal portion of the extein domain, the IN domain comprising an A block and a B block, the A block being at least 80% identical to the sequence Ch--Dp-hhh--G, designated respectively as positions A1 to A13, and the B block being at least 80% identical to the sequence G--h-hT--H-hhh, designated respectively as positions B1 to B14;
- wherein:
- a capital letter represents an amino acid designated by the single letter amino acid code;
- “h” represents a hydrophobic residue selected from the group consisting of G, B, L, I, A and M;
- “a” represents an acidic residue selected from the group consisting of D and E;
- “r” represents an aromatic residue selected from the group consisting of F, Y and W;
- “p” represents a polar residue selected from the group consisting of S, T and C;
- “-” represents any amino acid;
- and
- “*” represents optional gaps;
- and wherein:
- the residue encoded at position G7 is Q, W, F, L, I, Y, M, V, R, K, H, E or D;
- and/or
- the residue encoded at position G6 is L, N, D, W, F, I, M or Y;
- and/or
- the residue encoded at position B 11 is K, Y, F, W, H, Q or E;
- and/or
- the residue encoded at position G6 is A and G7 is Y;
- and/or,
- the residue encoded at position G6 is A and B 11 is K, Y, F, W, H, Q or E;
- and/or,
- the residue encoded at position F4 is E or Q;
- and/or,
- the residue encoded at position F13 is F, L or I;
- and/or,
- the residue encoded at position F14 is W, F, Y, L, K or R;
- and/or
- the residue encoded at position F15 is W or L;
- and/or,
- the residue at position B9 is not R or T and is a non-catalytic amino acid for an N—X acyl shift;
- and/or,
- the residue at position B 10 is not R or T and is a non-catalytic amino acid for an N—X acyl shift;
- and/or,
- the residue at position F2 is not R or T and is a non-catalytic amino acid for an N—X acyl shift;
- and/or,
- the residue at position F6 is not S, T or C and is a non-catalytic amino acid for a transesterification reaction involving a nucleophilic amino acid at position G8 attacking an ester or thioester bond.
An immunoglobulin molecule having no more than one linear terminal end and having the conformation of an immunoglobulin fold comprised of a heavy chain variable region attached by linkers to a light chain variable region, a first linker attaching the C-terminal region of the heavy chain variable region to the N-terminal region of the light chain variable region and a second linker attaching the N-terminal region of the heavy chain variable region to the C-terminal region of the light chain variable region, wherein the linkers comprise flexible covalent molecular links of at least approximately 50 Angstroms in length, wherein:
- the heavy chain variable region comprises one or more heavy chain framework regions selected from the group consisting of HFR1, HFR2, HFR3, and HFR4;
- and the heavy chain variable region further comprises one or more complementarity determining regions selected from the group consisting of CDR-H1, CDR-H2, CDR-H3;
- with the heavy chain framework and complementarity determining regions arranged in accordance with the formula HFR1--CDR-H1--HFR2--CDR-H2--HFR3--CDR-H3--HFR4;
- and,
- the light chain variable region comprises and one or more light chain framework regions selected from the group consisting of LFR1, LFR2, LFR3 and LFR4;
- and the light chain variable region further comprises one or more complementarity determining regions selected from the group consisting of CDR-L1, CDR-L2 and CDR-L3;
- with the light chain framework and complementarity determining regions arranged in accordance with the formula LFR1--CDR-L1--LFR27-CDR-L2--LFR3--CDR-L3--LFR4;
- and wherein,
- (i) HFR1 is a first heavy chain framework region consisting of a sequence of about 30 amino acid residues;
- (ii) HFR2 is a second heavy chain framework region consisting of a sequence of about 14 amino acid residues;
- (iii) HFR3 is a third heavy chain framework region consisting of a sequence of about 29 to about 32 amino acid residues;
- (iv) HFR4 is a fourth heavy chain framework region consisting of a sequence of 7 to about 9 amino acid residues;
- (v) CDR-H1 is a first heavy chain complementary determining region;
- (vi) CDR-H2 is a second heavy chain complementary determining region;
- (vii) CDR-H3 is a third heavy chain complementary determining region;
- (viii) LFR1 is a first light chain framework region consisting of a sequence of about 22 to about 23 amino acid residues;
- (ix) LFR2 is a second light chain framework region consisting of a sequence of about 13 to about 16 amino acid residues;
- (x) LFR3 is a third light chain framework region consisting of a sequence of about 32 amino acid residues;
- (xi) LFR4 is a fourth light chain framework region consisting of a sequence of about 12 to about 13 amino acid residues;
- (xii) CDR-L1 is a first light chain complementary determining region;
- (xiii) CDR-L2 is a second light chain complementary determining region;
- and,
- (xiv) CDR-L3 is a third light chain complementary determining region.
Dependencies are inferred from the claim text.